| Date Filed | Type | Description |
| 10/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 10/10/2023 |
SC 13G
| Cormorant Asset Management, LP reports a 5.5% stake in Marinus Pharmaceuticals, Inc. |
| 10/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/04/2023 |
4
| Chen Bihua (10% Owner) has filed a Form 4 on MoonLake Immunotherapeutics|
Txns:
| Bought 74,911 shares
@ $57.37, valued at
$4.3M
Bought 150,487 shares
@ $57.252, valued at
$8.6M
Bought 67,814 shares
@ $57.3188, valued at
$3.9M
|
|
| 08/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 07/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/16/2023 |
4
| Chen Bihua (10% Owner) has filed a Form 4 on Biomea Fusion, Inc.|
Txns:
| Granted 6,989 options to buy
@ $38.9, valued at
$271.9k
|
|
| 06/08/2023 |
3
| Cormorant Asset Management, LP (See below) has filed a Form 3 on GreenLight Biosciences Holdings, PBC |
| 04/24/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 04/24/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/03/2023 |
4
| Chen Bihua (10% Owner) has filed a Form 4 on Biomea Fusion, Inc.|
Txns:
| Bought 400,000 shares
@ $30, valued at
$12M
|
|
| 03/16/2023 |
4
| Cormorant Asset Management, LP (10% Owner) has filed a Form 4 on Ambrx Biopharma Inc.|
Txns:
| Bought 250,000 shares
@ $9.9531, valued at
$2.5M
Bought 250,000 shares
@ $10.5955, valued at
$2.6M
Bought 500,000 shares
@ $10.1485, valued at
$5.1M
|
|
| 03/13/2023 |
3
| Cormorant Asset Management, LP (10% Owner) has filed a Form 3 on Ambrx Biopharma Inc. |
| 03/13/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 17.7% stake in Ambrx Biopharma Inc. |
| 02/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 8.4% stake in Elevation Oncology, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 9.2% stake in Design Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 6.1% stake in GreenLight Biosciences Holdings, PBC |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 8.7% stake in Immuneering Corporation |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 6% stake in Ambrx Biopharma Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 6% stake in Monte Rosa Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 8% stake in BioAtla, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 8% stake in Aerovate Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 6.8% stake in Cabaletta Bio, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 4.7% stake in Arcellx, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 5.2% stake in Olema Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 5.3% stake in Altimmune, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 2.7% stake in Viridian Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 10% stake in Longboard Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 6.5% stake in Tarsus Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 6.3% stake in Astria Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 4% stake in VectivBio Holding AG |
|